Novel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon?

Indian Journal of Ophthalmology

Volumn 64, Issue 1, 2016, Pages 4-13

  Das, Arup ^a,b   McGuire, Paul ^a   Monickaraj, Finny ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

Author keywords

Blood retinal barrier; diabetes mellitus; diabetic macular edema; diabetic retinopathy; inflammation; vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; DRUG; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANTAGONISTS AND INHIBITORS; BLOOD RETINA BARRIER; DIABETIC RETINOPATHY; HUMAN; PATHOPHYSIOLOGY;

ANGIOGENESIS INHIBITORS; BLOOD-RETINAL BARRIER; DIABETIC RETINOPATHY; HUMANS; PHARMACEUTICAL PREPARATIONS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84961780826     PISSN: 03014738     EISSN: 19983689     Source Type: Journal    
DOI: 10.4103/0301-4738.178154     Document Type: Review

References (50)

1. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol 2007;14:179-83.
2. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556-64.
3. Frank RN. Diabetic retinopathy. N Engl J Med 2004;350:48-58.
4. Kuwabara T, Cogan DG. Retinal vascular patterns. VI. Mural cells of the retinal capillaries. Arch Ophthalmol 1963;69:492-502.
5. Das A, Frank RN, Weber ML, Kennedy A, Reidy CA, Mancini MA. ATP causes retinal pericytes to contract in vitro. Exp Eye Res 1988;46:349-62.
6. Frank RN. Etiologic mechanisms in diabetic retinopathy. In: Ryan SJ, editor. Retina. Vol. II. Philadelphia: Elsevier Mosby; 2006. p. 1241-70.
7. Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 2005;54:1615-25.
8. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol 2008;30:65-84.
9. Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A 1999;96:10836-41.
10. Rangasamy S, McGuire PG, Franco Nitta C, Monickaraj F, Oruganti SR, Das A. Chemokine mediated monocyte trafficking into the retina: Role of inflammation in alteration of the blood-retinal barrier in diabetic retinopathy. PLoS One 2014;9:e108508.
11. Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 2009;116:73-9.
12. Labriola LT, Kesen M, Csaky KG. Pharmacokinetics of anti-vascular endothelium growth factor pharmacological agents. In: Das A, Friberg TR, editors. Therapy for Ocular Angiogenesis. Philadelphia: Wolters Kluwer Lippincott Williams Wilkins; 2011. p. 140-53.
13. Heiduschka P, Fietz H, Hofmeister S, Schultheiss S, Mack AF, Peters S, et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007;48:2814-23.
14. Stewart MW. Aflibercept (VEGF-TRAP): The next anti-VEGF drug. Inflamm Allergy Drug Targets 2011;10:497-508.
15. Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 2014;98:1636-41.
16. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695. e1-15.
17. Bakbak B, Ozturk BT, Gonul S, Yilmaz M, Gedik S. Comparison of the effect of unilateral intravitreal bevacizumab and ranibizumab injection on diabetic macular edema of the fellow eye. J Ocul Pharmacol Ther 2013;29:728-32.
18. Avery RL. What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned? Br J Ophthalmol 2014;98 Suppl 1:i7-10.
19. Kurihara T, Westenskow PD, Bravo S, Aguilar E, Friedlander M. Targeted deletion of Vegfa in adult mice induces vision loss. J Clin Invest 2012;122:4213-7.
20. Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, et al. Primary end point (Six Months) results of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2009;116:2175-81.e1.
21. Do DV, Nguyen QD, Khwaja AA, Channa R, Sepah YJ, Sophie R, et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol 2013;131:139-45.
22. Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: The 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013;120:2013-22.
23. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): A 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010;33:2399-405.
24. Elman MJ, Ayala A, Bressler NM, Browning D, Flaxel CJ, Glassman AR, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology 2015;122:375-81.
25. Schmidt-Erfurth U, Lang GE, Holz FG, Schlingemann RO, Lanzetta P, Massin P, et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: The RESTORE extension study. Ophthalmology 2014;121:1045-53.
26. Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, Esposti SD, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: Report 3. Arch Ophthalmol 2012;130:972-9.
27. Do DV, Nguyen QD, Boyer D, Schmidt-Erfurth U, Brown DM, Vitti R, et al. One-year outcomes of the da Vinci study of VEGF trap-eye in eyes with diabetic macular edema. Ophthalmology 2012;119:1658-65.
28. Brown DM, Schmidt-Erfurth U, Do DV, Holz FG, Boyer DS, Midena E, et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology 2015;122:2044-52.
29. Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015;372:1193-203.
30. Heier JS, Bressler NM, Avery RL, Bakri SJ, Boyer DS, Brown DM. et al. Comparison of aflibercept, bevacizumab, and ranibizumab for treatment of diabetic macular edema: Extrapolation of data to clinical practice. JAMA Ophthalmol 2016;134:95-9.
31. Virgili G, Parravano M, Menchini F, Evans JR. Anti-vascular endothelial growth factor for diabetic macular oedema. Cochrane Database Syst Rev 2014;10:CD007419.
32. Avery RL, Gordon GM. Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: A systematic review and meta-analysis. JAMA Ophthalmol 2016;134:21-9.
33. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-77.e35.
34. Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011;118:626-35.e2.
35. Boyer DS, Yoon YH, Belfort R Jr., Bandello F, Maturi RK, Augustin AJ, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014;121:1904-14.
36. Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial. JAMA 2015;314:2137-46.
37. Das A, McGuire PG, Rangasamy S. Diabetic macular edema: Pathophysiology and novel therapeutic targets. Ophthalmology 2015;122:1375-94.
38. Nguyen Q. High Dose Ranibizumab for Diabetic Macular Edema: Month 24 Outcomes of the READ-3 Study (Ranibizumab for Edema of the mAcula in Diabetes-Protocol 3). Abstract, American Society of Retina Specialists Meeting; 2014.
39. Campochiaro PA, Channa R, Berger BB, Heier JS, Brown DM, Fiedler U, et al. Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: A phase I/II study. Am J Ophthalmol 2013;155:697-704, 704.e1-2.
40. Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration. Available from: http://www.ClinicalTrials. govIdentifier: NCT02510794. [Last accessed on 2016 Feb 17].
41. Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD). Available from: http://www.ClinicalTrials. govIdentifier: NCT02228304. [Last accessed on 2016 Feb 17].
42. Ohr Pharmaceutical Announces Initiation of Investigator Sponsored Trial of Squalamine Eye Drops in Diabetic Macular Edema. Available from: http://www.ohrpharmaceutical.com/media-center/press-releases/detail/174/ohr-pharmaceutical-announces-initiation-of-investigator. [Last accessed on 2015 Nov 18].
43. Rangasamy S, Srinivasan R, Maestas J, McGuire PG, Das A. A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy. Invest Ophthalmol Vis Sci 2011;52:3784-91.
44. Aerpio Therapeutics Announces Positive Results of a Phase 2a Study of AKB-9778 in Diabetic Macular Edema: The TIME-2 Trial. Available from: http://www.aerpio.com/news/Positive-Results-Phase-2a.pdf. [Last accessed on 2015 Nov 18].
45. Sfikakis PP, Grigoropoulos V, Emfietzoglou I, Theodossiadis G, Tentolouris N, Delicha E, et al. Infliximab for diabetic macular edema refractory to laser photocoagulation: A randomized, double-blind, placebo-controlled, crossover, 32-week study. Diabetes Care 2010;33:1523-8.
46. Scmidt M, Tisdale A, Lowden P, Kovalchin J, Furfine ES. Optimized IL-6 Blockade for the Treatment of Diabetic Macular Edema. Abstract, Association for Research in Vision and Ophthalmology (ARVO) Meeting; 2014.
47. A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults WithDiabetic Macular Edema. Available from: http://www.ClinicalTrials.govIdentifier: NCT01994291. [Last accessed on 2016 Feb 17].
48. Kita T, Clermont AC, Murugesan N, Zhou Q, Fujisawa K, Ishibashi T, et al. Plasma kallikrein-kinin system as a VEGF-independent mediator of diabetic macular edema. Diabetes 2015;64:3588-99.
49. KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema. Available from: http://www.kalvista.com/news/44/152/html. [Last accessed on 2015 Nov 18].
50. Allegro Ophthalmics Begins Phase 2 Clinical Trial of Luminate® (ALG-1001) for the Treatment of Diabetic Macular Edema. Available from: http://www.allegroeye.com/press/. [Last accessed on 2015 Nov 18].